Cytoreduction Surgery With Hyperthermic Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer Improves Progression-Free Survival, Especially in BRCA-Positive Patients-A Case-Control Study

BackgroundApproximately 70% of women diagnosed with advanced-stage ovarian cancer experience disease recurrence. Survival data were compared between a group of recurrent epithelial ovarian cancer (rEOC) patients treated by cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) and a matched group of rEOC patients treated by systemic chemotherapy only (without surgery). Treatment outcome in relation to the patients' BRCA status was compared. MethodsTwenty-seven rEOC patients treated by cytoreduction and HIPEC were selected from our database and matched (1:3) with 84 rEOC patients treated with chemotherapy only. Progression-free survival (PFS) and overall survival (OS) in the two groups were analyzed and compared. ResultsThe estimated median PFS was 15 months in the HIPEC group and 6 months in the systemic chemotherapy group (P=0.001). The median OS following HIPEC treatment has not been reached, since more than 70% of the women were alive at the time of analysis. The 5-year survival rate was significantly higher in the HIPEC treated patients compared to that of the controls (79% vs. 45%, P=0.016). BRCA status did not affect PFS. ConclusionsHIPEC after surgical cytoreduction in patients with rEOC appears beneficial compared to systemic chemotherapy treatment alone. The benefit is even greater in BRCA mutation carriers. J. Surg. Oncol. 2014 110:661-665. (c) 2014 Wiley Periodicals, Inc.